To compare the blood hormone levels, number of oocytes retrieved, and culture results cycles those using relugolix with adopting more conventional method cetrorelix. From December 2010 to February 2021, 251 [214 in cetrorelix (C) group 37 (R) group] ovarian stimulation GnRH antagonists were included study. Using E2 level per oocyte retrieval C (257 pg/ml) as a standard, R was divided into group...

Objectives: The adverse effect of chemotherapy on the proliferation granulosa cells has been indicated in recent studies. Gonadotropin-releasing hormone (GnRH) antagonists exert protective effects against side chemotherapy. In present study, we aimed to evaluate impact cetrorelix ovarian following administration thiotepa ovaries female mice. Materials and Methods: this experimental 30 adult Bal...

The aim of this study is to evaluate the effectiveness Dydrogesterone in PPOS protocols for IVF/ICSI cycles or Oocyte cryopreservation both blocking LH surge as well number metaphase II oocytes. 550 plus 186 oocyte from January 2018 December 2020, no age restriction. All patients were given Follitropin delta (Rekovelle®, Ferring Pharmaceuticals) Menotropin (Menopur®, a fixed daily SC dose. Clin...

BACKGROUND Reproductive function following chemotherapy is of increasing importance given that survival rates are improving. We assessed whether a gonadotropin-releasing hormone antagonist (GnRHant; cetrorelix) could promote ovarian protection against damage due to chemotherapy. METHODS Forty-two female Wistar rats were used in this study. Animals were divided into four groups: group I (n=9) ...

A depot preparation of the third-generation gonadotrophin-releasing hormone (GnRH) antagonist Cetrorelix (SB-75) was used for preoperative treatment in twenty premenopausal patients with symptomatic uterine fibroids who were to undergo surgery. In a prospective, open, randomized setting 60 mg of Cetrorelix pamoate salt was administered i.m. on cycle day 2. Patients were randomized for a second ...

In those clinical situations in which an immediate and profound suppression of gonadotrophins is desired, LHRH agonists have the disadvantage of producing an initial stimulatory effect on hormone secretion. Therefore, the use of GnRH antagonists which cause an immediate and dose-related inhibition of LH and FSH by competitive blockade of the receptors is much more advantageous. One of the most ...

We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting gonadotropin-releasing hormone (GnRH) antagonists. At single subcutaneous injections of 0.3 to 10 microg/kg in rats, degarelix produced a dose-dependent suppression of the pituitary-gonadal axis as revealed by the decrease in plasma luteinizing hormone (LH) and testosteron...